Discovery and characterization of taspoglutide, a novel analogue of human glucagon‐like peptide‐1, engineered for sustained therapeutic activity in type 2 diabetes

We have discovered an Aib⁸(,)³⁵-substituted analogue of native hGLP-1(7-36)NH₂ (BIM-51077) that retains the structure of the native peptide, and has similar activity and enhanced stability. A sustained-release formulation of this molecule (taspoglutide) is in phase-3 clinical development.